SG-5-00455 / Second Genome - LARVOL DELTA

Second Genome Presents Data at the World Microbe Forum Demonstrating Application of its Computational Platform sg-4-sight to Identify Peptides that Have the Potential to Modulate T Cell Activity in Inflammatory Bowel Disease (IBD) (PRNewswire) - "Second Genome...presented data demonstrating the use of its Multi-Technology Meta-Analysis (MTMA) Algorithm to identify microbial strains and peptides with therapeutic potential in inflammatory bowel disease (IBD) patients. The data were presented at the World Microbe Forum, a collaboration between the American Society for Microbiology (ASM), Federation of European Microbiological Societies (FEMS) and several other societies, held virtually June 20–24...'We look forward to providing further updates on the programs resulting from this approach, including SG-2-0776 for the treatment of IBD, and the rest of our precision therapeutics and biomarker pipelines.'"

eHealth • Inflammatory Bowel Disease

IDENTIFICATION AND DEVELOPMENT OF A 1ST IN CLASS NATURALLY-DERIVED PROTEIN THAT DRIVES MUCOSAL HEALING AND IS ORALLY DELIVERED BY AN ENGINEERED CELLULAR THERAPY TARGETING THE GASTRO-INTESTINAL TRACT (DDW 2022) - "This pathway will provide the basis for a potential biomarker to identify patients likely to respond to SG-5-00455.SG-5-00455, through its novel mechanism of action and oral delivery to directly target tissue repair pathways in the GI-tract, offers the potential to address a large critical need in IBD. Moreover, bioinformatic analysis indicates that we can identify a subset of patients that is likely to respond to SG-5-00455."

Fibrosis • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic, Improves Epithelial Barrier Function and Promotes Mucosal Healing in Inflammatory Bowel Disease (PRNewswire) - P=NA | N=NA | "Second Genome...presented data demonstrating the Company's development candidate, SG-5-00455, improves epithelial barrier function and promotes mucosal healing by effectively inhibiting plasminogen activator inhibitor (PAI)-1/2 activity in the intestines. The data were presented at Digestive Disease Week 2022 Annual Meeting, held May 21-24 virtually and in San Diego, California."

Clinical data • Immunology • Inflammatory Bowel Disease

Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD) (PRNewswire) - "Second Genome...yesterday hosted a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator inhibitor (PAI)-1/2 in inflammatory bowel disease (IBD), and a briefing on SG-5-00455, the Company's development candidate for the treatment of IBD." "

Preclinical • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Identification and development of a 1st in class naturally-derived protein that drives mucosal healing and is orally delivered by an engineered cellular therapy targeting the gastro-intestinal tract (ECCO-IBD 2022) - "SG-5-0455 treatment did not result in systemic exposure, driving its therapeutic activity in a GI-localized manner by targeting pathways related to tissue injury and fibrinolysis. Conclusion SG-5-00455, through its novel mechanism of action and oral delivery to directly target tissue repair pathways in the GI-tract, offers the potential to address a large critical need in IBD."

Inflammatory Bowel Disease • LBP

Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of European Crohn's and Colitis Organization (ECCO) (PRNewswire) - "The naturally derived protein SG-2-0776 demonstrated direct binding of PAI-1, functional inhibition of PAI-1/2 and improvement in epithelial barrier function in vitro. In pre-clinical colitis models, oral administration of SG-5-00455 reduced pathology scores for inflammation and restored barrier function levels, as well as improved dysregulated tissue repair and fibrosis-associated gene expression and proteins levels....SG-5-00455 is currently in IND-enabling studies, and the Company expects to file an investigational new drug (IND) application with the U.S. FDA in the second half of 2022."

IND • Preclinical • Immunology • Inflammatory Bowel Disease

Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23 (PRNewswire) - "Second Genome...announced that it will host a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator inhibitor (PAI)-1/2 in inflammatory bowel disease (IBD) on Wednesday, February 23, 2022, from 12:00 – 1:00 p.m. EST....In addition to a brief pre-clinical program overview of SG-5-00455, Second Genome's development candidate for the treatment of IBD..."

Preclinical • Immunology • Inflammatory Bowel Disease

Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD) (PRNewswire) - Second Genome...today announced that the Company will advance SG-5-00455, which targets plasminogen activator inhibitor (PAI)-1/2, as a development candidate for the treatment of inflammatory bowel disease (IBD). The Company will present new preclinical data on SG-5-00455 at the virtual 17th Congress of European Crohn's and Colitis Organization (ECCO) on February 18, 2022."

Preclinical • Immunology • Inflammatory Bowel Disease

Second Genome Granted U.S. Patent for Proteins for the Treatment or Prevention of Epithelial Barrier Function Disorders (PRNewswire) - "Second Genome...announced that the U.S. Patent and Trademark Office issued a U.S. patent, No. 11,174,293 B2, entitled, 'Proteins for the Treatment of Epithelial Barrier Function Disorders.' The patent covers a potential first-in-class therapeutic that improves mucosal healing, and other novel proteins and pharmaceutical compositions comprising those proteins that have application in the treatment or prevention of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, and other epithelial barrier function disorders...Second Genome expects to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2022."

IND • Patent • Immunology • Inflammatory Bowel Disease

Second Genome Presents Preclinical Data at Crohn’s & Colitis Foundation’s IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455 (PRNewswire) - "Second Genome...presented preclinical data from its mucosal healing program in inflammatory bowel disease (IBD) at the Crohn's & Colitis Foundation's IBD Innovate: Product Development in Crohn's & Colitis® virtual conference held November 18-19, and announced its Corporate Circle membership for a three-year term....'Our preclinical findings show bacteria associated with healthy human microbiota that are reduced in ulcerative colitis patients play an important role in gut homeostasis by producing proteins that display a novel mechanism of action related to extracellular matrix (ECM) binding, improved barrier function and mucosal healing in response to epithelial damage...'"

Preclinical • Inflammatory Bowel Disease • Ulcerative Colitis